Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider

24 Nov 2025 16:40 CET

Oslo, Norway, November 24, 2025 - Primary insider Michael Engsig, Chief
Executive Officer of Nykode Therapeutics ASA, has today acquired 46,356 shares
in Nykode Therapeutics ASA at a price of NOK 2.16 per share. Following the
transaction, Michael Engsig holds 118,150 shares in Nykode Therapeutics ASA.

Please see further details in the attached document.

More information:
Access the news on Oslo Bors NewsWeb site

660428_Attachment 251124.pdf